Onco360 Named To Limited Network For IMBRUVICA™ (ibrutinib)

NEW YORK - Nov. 13, 2013 - PRLog -- Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib) capsules, now approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

“As one of the select few Specialty Pharmacies in the network, Onco360 is very proud to have been chosen by Pharmacyclics & Janssen Biotech, Inc.,” said Burt Zweigenhaft, CEO of Onco360.

IMBRUVICA™ is commercially available immediately through Onco360 and its network of OncoMed Pharmacies.  Orders can be placed by:

·       Downloading and IMBRUVICA™ Order Form at www.Onco360.com and faxing it to 877-662-6355

·       Calling 877-662-6633

·       Or e-Prescribing to OncoMed, The Oncology Pharmacy

“We are committed to maintaining the high level of performance and quality the Onco360 Oncology Pharmacy dispensing and clinical support model.  Our focus and innovation in the field of Oncology Pharmacy, coupled with high-touch services and clinical expertise, help make Onco360 a great partner for the IMBRUVICA™ Specialty Pharmacy network,” said Amvrosios Ioannidis, Chief Brand & Marketing Officer of Onco360, adding that, “Onco360, and the entire network, will offer best-in-class support to patients and physicians using IMBRUVICA™.”

“Cancer patients, and the physicians that treat them, require a high level of service,” said Mr. Zweigenhaft. “We are delighted and honored to be entrusted in the IMBRUVICA™ network.  As a company, we are passionate about patient care, and proud of our unique Oncology Pharmacy model,” Mr. Zweigenhaft went on to say.

Eligible patients who are prescribed IMBRUVICA™ may receive access support through the YOU&i Access Program.  More information is available at 877-877-3536 or at www.Youandiaccess.com.

Please see the full prescribing information at www.IMBRUVICA.com.